Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Alliance Healthcare pledges to reduce single-use plastic by 60 per cent in three years

Alliance Healthcare UK has pledged to reduce the use of single-use secondary plastic by 60 per cent within three years.

Measures undertaken by the company to reduce its carbon footprint, which were initiated last year, have carried on despite the challenges thrown by the Covid-19 pandemic.


Alliance Healthcare UK recently started to roll out new reusable tote bins to replace plastic bags and cardboard packaging to its Health and Beauty customers.

Work being carried out across the company, as part of its 'Getting drastic with plastic' campaign, includes removal of invoice bags, switching to paper bubble wrap and investment in reusable totes, the company said on Tuesday (Oct 27).

“We recognise that as an industry leader we must pioneer the way in reducing our impact on the environment, managing director Julian Mount said. "Our three year plan will entail an ambitious 35 per cent reduction of single-use plastic secondary packaging by September 2021.”

Aiming to reduce the overall use of single-use plastic by 60 per cent by September 2022, three years from when the initiative started in 2019, Alliance Healthcare UK has already saved over 39 tonnes of single-use plastic items. By the close of the next fiscal-year the aim is to save a total of 131 tonnes, the company added.

“Every year, over two million units of single-use plastic bags and cardboard boxes will be removed from our operations, considerably lessening Alliance Healthcare’s carbon footprint,” said Jon Cornforth, the national environment health and safety manager.

Several businesses in the UK have increased their push on cutting plastic pollution since a 2018 David Attenborough series, Blue Planet II, drew wider attention to the problem.

Community pharmacies have been banned from supplying plastic straws and plastic stemmed cotton buds to customers in England after the latest environmental protection regulations came into force on October 1, 2020.

More For You

Astrazeneca Office Building  Outlook

British Medical Journal has found data discrepancy during the crucial clinical trials of AstraZeneca's heart drug ticagrelor.

iStock

Top medics question trials of AstraZeneca's anti-clotting pill

The effectiveness of anti-clotting pill ticagrelor is now under a cloud, with some experts claiming that AstraZeneca misreported data when the trials were conducted more than a decade ago.

Sold as Brilinta, the pill was approved for use on the NHS in 2011 after trials claimed it could prevent one in five deaths after a heart attack, and the generic versions of the drug are scheduled for this year.

Keep ReadingShow less
Boots pension dispute

The Pensions Ombudsman has begun an investigation into the decision by the Trustees of Boots Pension Scheme to remove members' option to retire on an unreduced pension at age 60.

iStock

Pensions Ombudsman probing Boots pension dispute

The Pensions Ombudsman has begun an investigation into the decision by the Trustees of Boots Pension Scheme to remove members' option to retire on an unreduced pension at age 60.

According to the Pharmacists' Defence Association (PDA), the ombudsman has decided to take a ‘lead case’ approach, as several members have been affected by the issue.

Keep ReadingShow less
23andMe

More than 150,000 UK residents had their personal information taken by hackers during a data breach in 2023.

iStock

UK watchdog fines 23andMe £2.31m for data breach

Genetic testing firm 23andMe has been fined £2.31 million by a UK watchdog over a 2023 data breach, when the personal information of seven million people across the world was stolen.

The Information Commissioner's Office (ICO) said the California-based company, which later filed for bankruptcy, failed to put adequate measures in place to secure sensitive user data.

Keep ReadingShow less
Henry Gregg, new Chief Executive of the National Pharmacy Association.
Henry Gregg
Henry Gregg

Community pharmacy voices need to be ‘heard really loud’, new NPA chief tells Pharmacy Business

Henry Gregg, the new chief executive of the National Pharmacy Association (NPA), believes community pharmacies have a right to have insight into discussions relating to the pharmacy funding contract.

Currently, Community Pharmacy England (CPE) solely negotiates the elements of the Community Pharmacy Contractual Framework (CPCF) with the Department of Health and Social Care (DHSC) and NHS England.

Keep ReadingShow less
Patient care

The NHS said the benefits were "too small to justify the additional cost"

NHS rejects Alzheimer's drugs shown to delay early-stage of disease

Two new treatments for Alzheimer's disease will not be offered on the NHS due to high costs and "too small" benefits.

Donanemab and Lecanemab have been hailed as breakthrough treatments for slowing down the symptoms of early-stage Alzheimer's, the most common type of dementia.

Keep ReadingShow less